Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT)

Folkert, Michael R.; Timmerman, Robert

doi:10.1016/j.addr.2016.11.005

Cited by 80 publications

(56 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2015, Ost et al 42 published a pooled analysis of all the available data up to that moment. 19,[25][26][27][28]43,44 With a total of 119 patients, median distant clinical PFS was 21 months (95% confidence interval, [15][16][17][18][19][20][21][22][23][24][25][26][27]. Three-and five-year distant PFS were 31% and 15%, respectively.…”

Section: Summary Of Evidencementioning

confidence: 99%

“…Treatment techniques have also been improved, of which are noteworthy minimally invasive surgeries and stereotactic body radiation therapy (SBRT). SBRT uses precise targeting to deliver ablative radiation doses to tumours, while keeping a low toxicity profile . As a result, interest in using local approaches to the direct treatment of metastasis has significantly increased.…”

Section: Introductionmentioning

confidence: 99%

“…SBRT uses precise targeting to deliver ablative radiation doses to tumours, while keeping a low toxicity profile. 15 As a result, interest in using local approaches to the direct treatment of metastasis has significantly increased. The clinical implication would be the long-term disease control, with the potential to postpone palliative systemic treatment until widespread progression.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review

et al. 2018

View full text Add to dashboard Cite

The purpose of this study is to evaluate the effectiveness and safety of stereotactic body radiation therapy (SBRT) in the management of oligometastatic recurrent prostate cancer (PCa) by means of a systematic review. Six databases were searched (CENTRAL, Embase, LILACS, PubMed, Scopus and Web of Science). Additionally, hand-searching and grey literature search were performed. The main outcomes were progression-free survival (PFS) and toxicity rates. Androgen deprivation therapy-free survival (ADT-FS), local control, pattern of recurrence, cancer-specific survival and overall survival were also assessed. Risk of bias and quality of evidence were judged with the aid of specific tools. Fourteen studies were included, involving 661 patients and 899 lesions (561 nodal, 336 bone, 2 liver). Median PFS and ADT-FS were around 1 to 3 years. Local control rates varied from 82 to 100% among researches with low risk of bias. Acute and late grade 2 toxicity was observed in 2.4% and 1.1% of the patients, respectively. One case of acute and two cases of late grade 3 toxicity were registered. Only one randomized study addresses this topic. Although it does not meet all the eligibility criteria, it is useful for the discussion. A quantitative analysis was not possible, nor were subgroup analyses, due to the significant heterogeneity of the interventions and outcomes reported. Longer follow-up period is required. SBRT seems to be a safe approach to metastatic lesions that might provide disease control and defer androgen deprivation therapy (ADT). Local control is better when higher radiation doses are employed.

show abstract

Section: Summary Of Evidencementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, advances in stereotactic body radiotherapy (SBRT) have made it possible to administer highly focused treatments of high-dose radiation in one or a few fractions, while sparing the normal surrounding tissues with a rapid dose fall-off. In addition, recent evidence suggests that SBRT indirectly leads to tumor cell death by compromising the intra-tumor microenvironment and by the abscopal effect, which is induced by the subsequent immune boost [6,7]. …”

Section: Introductionmentioning

confidence: 99%

Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors

et al. 2017

View full text Add to dashboard Cite

PurposeTo evaluate the outcomes of stereotactic body radiation therapy (SBRT) for patients with liver oligo-recurrence and oligo-progression from various primary tumors. Materials and MethodsBetween 2002 and 2013, 72 patients with liver oligo-recurrence (oligo-metastasis with a controlled primary tumor) and oligo-progression (contradictory progression of a few sites of disease despite an overall tumor burden response to therapy) underwent SBRT. Of these, 9 and 8 patients with uncontrollable distant metastases and patients immediate loss to follow-up, respectively, were excluded. The total planning target volume was used to select the SBRT dose (median, 48 Gy; range, 30 to 60 Gy, 3–4 fractions). Toxicity was evaluated using the Common Toxicity Criteria for Adverse Events v4.0.ResultsWe evaluated 55 patients (77 lesions) treated with SBRT for liver metastases. All patients had controlled primary lesions, and 28 patients had stable lesions at another site (oligo-progression). The most common primary site was the colon (36 patients), followed by the stomach (6 patients) and other sites (13 patients). The 2-year local control and progression-free survival rates were 68% and 22%, respectively. The 2- and 5-year overall survival rates were 56% and 20%, respectively. The most common adverse events were grade 1–2 fatigue, nausea, and vomiting; no grade ≥3 toxicities were observed. Univariate analysis revealed that oligo-progression associated with poor survival. ConclusionSBRT for liver oligo-recurrence and oligo-progression appears safe, with similar local control rates. For liver oligo-progression, criteria are needed to select patients in whom improved overall survival can be expected through SBRT.

show abstract

“…12 SBRT has emerged as standard therapy for early stage lung cancer, as well as for localised prostate cancer and primary pancreas, liver, kidney and breast cancer, as well as for limited metastatic disease. 12,13 Its extension to cardiac tissue came with the recognition that stereotactic therapy gated to cardiac motion can effectively treat defined volumes in the heart.…”

Section: Non-invasive Ablation Of Ventricular Tachycardiamentioning

confidence: 99%

Non-invasive Cardiac Radiation for Ablation of Ventricular Tachycardia: a New Therapeutic Paradigm in Electrophysiology

Kim

Davogustto

Stevenson

et al. 2018

Arrhythmia &Amp; Electrophysiology Review

View full text Add to dashboard Cite

Myocardial scars from infarction or replacement fibrosis in nonischaemic cardiomyopathies are the common substrate for sustained monomorphic ventricular tachycardia (VT). Stereotactic Body Radiation Therapy: Basic Concepts and ApplicationsStereotactic radiotherapy involves directing highly focused external beam radiation therapy to target a well-defined and demarcated volume of tissue. 8 Its use was first described to treat brain tumours with the goal of delivering a high therapeutic dose to the lesion of interest while minimising radiation to the surrounding normal tissue. 9 The application of this technology to other organs in the body was initially limited by physiological motion and difficulties in accurate targeting. 10However, with advances in imaging, gating, tracking and intensity modulation, the use of stereotactic radiation has been expanded to other organs, and is now referred to as stereotactic body radiation therapy (SBRT). 11 Megavoltage photons and protons can be used for SBRT, and during irradiation, multiple static beams or rotational beams are generally oriented to an isocentre. The key requirements of SBRT are accurate target delineation and motion compensation strategies. 10,11 Accurate target delineation requires use of advanced imaging strategies that allow differentiating healthy from affected tissue. Motion compensation can be achieved with:• dampening/inhibition, which aims to limit respiratory motion using abdominal compression or breath-hold manoeuvres; AbstractNon-invasive ablation of cardiac tissue to control ventricular tachycardia (VT) is a novel therapeutic consideration in the management of ventricular arrhythmias associated with structural heart disease.

show abstract

Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT)

Cited by 80 publications

References 144 publications

Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review

Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review

Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors

Non-invasive Cardiac Radiation for Ablation of Ventricular Tachycardia: a New Therapeutic Paradigm in Electrophysiology

Contact Info

Product

Resources

About